Checkpoint Therapeutics, Inc. (CKPT) financial statements (2022 and earlier)

Company profile

Business Address 2 GANSEVOORT STREET
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments54,73540,77226,07721,99519,22535,086
Cash and cash equivalents54,73540,77226,07721,99519,22535,086
Other current assets1720261,532331821
Other undisclosed current assets9761,8048631,3721,85771
Total current assets:55,72842,59626,96624,89921,41335,978
Noncurrent Assets
TOTAL ASSETS:55,72842,59626,96624,89921,41335,978
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:24,9196,3677,25712,3175,7623,355
Accounts payable16,1393,4383,0799,7503,6452,473
Accrued liabilities233385268377246213
Employee-related liabilities843535414439405291
Other undisclosed accounts payable and accrued liabilities7,7042,0093,4961,7511,466378
Due to related parties1,063850862776610318
Other liabilities  3,496   
Other undisclosed current liabilities  (3,496)   
Total current liabilities:25,9827,2178,11913,0936,3723,673
Noncurrent Liabilities
Total liabilities:25,9827,2178,11913,0936,3723,673
Stockholders' equity
Stockholders' equity attributable to parent, including:29,74635,37918,84711,80615,04132,305
Common stock 65322
Common stock, value, subscriptions6,5984,6172,5101,7482,2963,919
Additional paid in capital223,001173,947136,442105,45171,77264,736
Accumulated deficit(199,862)(143,192)(120,111)(95,397)(59,030)(36,353)
Other undisclosed stockholders' equity attributable to parent911111
Total stockholders' equity:29,74635,37918,84711,80615,04132,305
TOTAL LIABILITIES AND EQUITY:55,72842,59626,96624,89921,41335,978

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues2681,0691,7083,5061,7252,570
Revenue, net1,7252,570
Revenue from related parties2681,0691,7083,506
Gross profit:2681,0691,7083,5061,7252,570
Operating expenses(56,991)(24,270)(26,558)(40,246)(24,500)(24,734)
Operating loss:(56,723)(23,201)(24,850)(36,740)(22,775)(22,164)
Nonoperating income (expense)5312013637398(297)
Investment income, nonoperating531201361489847
Other nonoperating income   225  
Interest and debt expense     (344)
Net loss:(56,670)(23,081)(24,714)(36,367)(22,677)(22,805)
Other undisclosed net income attributable to parent     344
Net loss available to common stockholders, diluted:(56,670)(23,081)(24,714)(36,367)(22,677)(22,461)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(56,670)(23,081)(24,714)(36,367)(22,677)(22,805)
Comprehensive loss, net of tax, attributable to parent:(56,670)(23,081)(24,714)(36,367)(22,677)(22,805)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: